Friday, 29 March, 2024
HomeImmunologyGenome analysis to boost standard drug screening

Genome analysis to boost standard drug screening

New pharmaceuticals to fight auto-immune diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis, may be identified more effectively by adding genome analysis to standard drug screening. [s]Health-Canal[/s] reports that this is according to a new study by a research team led by [b]UC San Francisco[/b] and [b]Harvard[/b] researchers, in collaboration with [b]Tempero[/b] and [b]GlaxoSmithKlein[/b]. The scientists combined drug screening with state-of-the-art techniques for analysing the genome, leading to three small molecules that improved symptoms in a mouse form of multiple sclerosis. ‘Our studies provide … both insight into how transcriptional regulators shape the identity and affect the development of Th17 cells, and also into how different drug molecules might affect these regulatory circuits in the cells,’ team leader Dr Alexander Marson, UCSF Diabetes Centre, said.

[link url=http://www.healthcanal.com/immune-system/50427-autoimmune-diseases-may-succumb-to-new-drug-strategy.html]Full Health-Canal report[/link]
[link url=http://www.cell.com/immunity/abstract/S1074-7613(14)00118-6]Immunity research summary[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.